1 Untargeted proteomics enables ultra-rapid variant prioritization in mitochondrial

2 and other rare diseases

3

Daniella H. Hock^{1,2,3,*}. Nikeisha J. Caruana^{1,4}. Liana N. Semcesen¹. Nicole J. Lake⁵. Luke 4 E. Formosa⁶, Sumudu S. C. Amarasekera², Tegan Stait², Simone Tregoning², Leah E. 5 Fraiman², David R. L. Robinson¹, Megan Ball^{2,10,12}, Boris Reljic^{1,6}, Bryony Ryder⁷, Mathew 6 J. Wallis^{8,9}, Anand Vasudevan¹⁰, Cara Beck³, Heidi Peters^{11,12}, Joy Lee^{3,11}, MitoMDT 7 Diagnostic Network for Genomics and Omics^{**}, Vasiliki Karlaftis^{2,12}, Chantal Attard^{2,12}, 8 Paul Monagle^{2,12,13,14}, Amanda Samarasinghe², Rosie Brown^{2,3}, Weimin Bi^{15,16}, Monkol 9 Lek⁵, Robert McFarland^{17,18}, Robert W. Taylor^{17,18}, Michael T. Ryan⁶, Zornitza Stark^{2,3,12}, 10 John Christodoulou^{2,3,12}, Alison G. Compton^{2,3,12}, David R. Thorburn^{2,3,12*}, David A. 11 Stroud^{1,2,3*} 12

- 13
- 14 Affiliations
- 15 ¹Department of Biochemistry and Pharmacology, Bio21 Molecular Science and
- 16 Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia
- ¹⁷ ²Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia
- ¹⁸ ³Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne,
- 19 VIC, 3052, Australia
- ⁴Institute for Health and Sport (iHeS), Victoria University, Melbourne, VIC, 3011, Australia
- ⁵Department of Genetics, Yale School of Medicine, New Haven, CT 06510 USA
- ⁶Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery
- 23 Institute, Monash University, 3800, Melbourne, Australia
- ⁷Paediatric and Adult National Metabolic Service, Te Toka Tumai, Te Whatu Ora Health
- 25 New Zealand, Auckland, New Zealand
- ⁸Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS 7001,
- 27 Australia
- ⁹School of Medicine and Menzies institute for Medical Research, University of Tasmania,
- 29 Hobart, TAS 7001, Australia
- ¹⁰Royal Women's Hospital, Melbourne, VIC, 3052, Australia
- ¹¹Department of Metabolic Medicine, Royal Children's Hospital, Melbourne, VIC 3052,
- 32 Australia
- ¹²Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia
- ¹³Department of Haematology, Royal Children's Hospital, Parkville VIC, Australia
- ¹⁴Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia

¹⁵Department of Molecular and Human Genetics, Baylor College of Medicine, Houston,

- 37 TX, 77030, USA.
- ¹⁶Baylor Genetics, Houston, TX, 77021, USA.

¹⁷Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of

40 Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United41 Kingdom

- ¹⁸NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon
 Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK
- 44

*To whom correspondence should be addressed. Tel: +61-3-8344-8317 Email:
<u>daniella.hock@unimelb.edu.au</u> (Daniella H. Hock) Tel: +61-3-8341-6235 Email:
<u>david.thorburn@mcri.edu.au</u> (David R. Thorburn); Tel: +61-3-8344-7316; Email:
<u>david.stroud@unimelb.edu.au</u> (David A. Stroud).

49

**MitoMDT Diagnostic Network for Genomics and Omics members are listed at the endof the manuscript.

52

53 Abstract

54 Only half of individuals with suspected rare diseases receive a definitive genetic diagnosis following genomic testing. A genetic diagnosis allows access to appropriate patient care 55 56 and reduces the number of potentially unnecessary interventions and related healthcare 57 costs. Here, we demonstrate that an untargeted quantitative mass-spectrometry 58 approach quantifying >6,000 proteins in primary fibroblasts representing >80% of known 59 mitochondrial disease genes can provide functional evidence for 88% of individuals in a 60 cohort of known primary mitochondrial diseases. We profiled >90 individuals, including 28 with confirmed disease and diagnosed 6 individuals with variants in both nuclear and 61 62 mitochondrial genes. Lastly, we developed an ultra-rapid proteomics pipeline using 63 minimally invasive peripheral blood mononuclear cells to support upgrade of variant pathogenicity in as little as 54 hours in critically ill infants with suspected mitochondrial 64 disorders. This study supports the integration of a single untargeted proteomics test into 65 routine diagnostic practice for the diagnosis of rare genetic disorders in clinically 66 actionable timelines, offering a paradigm shift for the functional validation of genetic 67 68 variants.

69

70 Introduction

71 Despite advances in genomic sequencing approaches, only 35-70% of individuals with 72 suspected rare disease receive a molecular diagnosis following whole exome sequencing (WES) or whole genome sequencing (WGS)¹⁻⁵. Negative cases generally remain 73 undiagnosed due to variants being refractory to short-read sequencing approaches or 74 75 when detected variants of uncertain significance (VUS, Class 3) are detected, requiring functional evidence to be upgraded to likely pathogenic (Class 4) or pathogenic (Class 5). 76 Mitochondrial disease is an umbrella term for a group of over 300 rare monogenic 77 disorders affecting mitochondrial energy production in the form of ATP⁶. These disorders 78 79 can arise from sporadic or inherited variants in either nuclear or mitochondrial DNA (mtDNA), presenting at any stage of life with a myriad of symptoms affecting either a 80 single organ or in a multisystemic manner⁷. Mitochondrial diseases affect approximately 81 1 in 5,000 live births⁸ with limited treatments available, reinforcing the importance of a 82 83 genomic diagnosis for early intervention in affected individuals. A genomic diagnosis also 84 facilitates informed reproductive options such as prenatal diagnosis (PND) and assisted 85 reproductive technologies such as preimplantation genetic testing (PGT) and 86 mitochondrial replacement therapy (MRT)⁹.

Functional approaches to assess VUS pathogenicity in mitochondrial disease have 87 historically relied on targeted and low throughput tests such as respiratory chain 88 89 enzymology (RCE), SDS-polyacrylamide gel electrophoresis (PAGE) or Blue Native (BN)-PAGE and immunoblotting. RCE assesses the activity of the mitochondrial respiratory 90 91 chain complexes I-IV and is typically normalised to the activity of a single enzyme, citrate 92 synthase (CS), to account for variability in mitochondrial content determined by sample 93 quality, amount and storage¹⁰. Western blotting has also been used for the confirmation 94 of VUS pathogenicity based on protein abundance or differential size, although it relies on having a strong genetic lead for disease causation from genomic data and the 95 commercial availability of antibodies for the desired protein. 96

Other non-targeted functional approaches such as transcriptomics and proteomics have
also been applied to the diagnosis of mitochondrial diseases. In selected cohorts,
transcriptomics has been shown to increase the diagnosis of mitochondrial disorders by
10-16%^{11, 12} and other rare Mendelian disorders by 7-17%¹³⁻¹⁵. Although transcriptomic

101 analysis can be a powerful tool in assessing pathogenicity of intronic and splice variants, 102 this approach has limited power in offering functional information on missense variants, 103 one of the most common and challenging classes of variants to assess^{16, 17}. Splice variants are predicted to account for only 10% of pathogenic variants associated with 104 105 autosomal recessive disorders¹⁸, in line with current diagnostic rates achieved by 106 transcriptomics. Missense variants, on the other hand, account for 60% of pathogenic 107 variants¹⁸ and approximately 40% of them are expected to result in reduced protein levels due to protein instability and turnover¹⁹. Proteomics can detect such changes and has 108 109 been demonstrated to contribute to the diagnosis of Mendelian disorders by providing 110 functional evidence for not only missense variants but also splice, deep intronic and copy 111 number variants ^{11, 20-25}. Despite this, there is a lack of data to inform the general utility of 112 proteomics in rare disease diagnoses as an untargeted approach like genomics and 113 transcriptomics.

Here, we present a systematic analysis demonstrating the utility of proteomics in the detection of rare mitochondrial disorders and provide the first validated pipeline for ultrarapid functional testing using peripheral blood mononuclear cells (PBMCs). Reference proteomics data and associated bioinformatics tools for performing the proteome analysis approaches developed for these investigations can be applied to user-uploaded data through our interactive web tool (<u>https://rdmassspec.shinyapps.io/RDMSExplorer/</u>).

120

121 **Results**

122 To validate our untargeted proteomic approach in the detection of mitochondrial disorders, 123 we first analysed primary fibroblast cell lines from a cohort of 24 patients with confirmed 124 genetic diagnoses based on known pathogenic or likely pathogenic nuclear or mtDNA-125 encoded variants. This validation cohort (VC) included cell lines with defects in subunits 126 or assembly factors for each of the five individual OXPHOS complexes as well as defects 127 of mtDNA translation that impact multiple complexes, causing a combined OXPHOS 128 biochemical defect (Fig 1A, Supplementary Table 1). Principal component analysis 129 showed that proteomes segregate according to their primary defect (Fig. 1B) and 130 hierarchical clustering of OXPHOS subunits and assembly factors identified clear profiles 131 (Supplementary Fig. 1A, B). We have previously shown similar profiles to be present in

gene-edited HEK293T knockout of Complex I subunits²⁶. Comparison of mitochondrial
proteomes from our validation cohort of fibroblast cell lines and corresponding geneedited HEK293T knockout cell lines (knockout cohort, KC) showed good correlation of
dysregulated proteins (Supplementary Fig. 2A, B).

136

137 The maximum theoretical coverage of known mitochondrial disease gene products from the fractionated library was 80%, with a routine coverage of 64% in a standard 95-minute 138 139 library-supported DIA run from fibroblast samples (Fig. 1C). Our approach could also 140 detect proteins corresponding to 37% of the Mendeliome (i.e., encoded by known disease genes) in a standard 95-minute run, supporting the potential utility of proteomics as a 141 142 disease agnostic test in the resolution of many rare monogenic disorders. In terms of 143 variant type in the validation cohort, the most common type was nuclear single nucleotide variants (48%) followed by mtDNA single nucleotide variants (16%), indel (16%), splice 144 145 site (13%) and deep intronic (6%) (Fig. 1D). We quantified the abundance of the protein 146 of interest in 67% of our investigations with the most common outcome being the protein 147 abundance readily quantified in controls and absent in proband (42%) followed by a decrease in the patient relative to controls (21%) (Fig. 1E). In 29% of cases the protein 148 149 of interest was not detected in either proband or control fibroblasts. For the cases where the protein was identified in both proband and control fibroblasts, analysis of the standard 150 151 deviation show that ND1 abundance in VC6 (MT-ND1) was 97% relative to control median 152 and within the control distribution, while ND5 abundance in VC12 (*MT-ND5*) was 118% 153 relative to control median and approximately 3 standard deviations above the control 154 median (Fig. 1F). Other identified proteins were outside the control range and >9 standard 155 deviations below control median (Fig. 1F).

- 156
- 157



158

159 Figure 1. Study design and validation cohort analysis A – Quantitative proteomics experimental design 160 overview. A fibroblast validation cohort (VC), HEK293T knockout cohort (KC), undiagnosed patient cohort 161 (UDP) and supporting cohort (SC) prepared using S-Trap[™] columns. Digested peptides were subjected to 162 Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) Data Independent Acquisition (DIA). 163 Pooled control peptides were fractionated using strong cation-exchange (SCX) chromatography and data 164 acquired as Data Dependent Acquisition (DDA) to generate spectral libraries for fibroblasts (Fbs), HEK293T 165 (HEK) and PBMCs. Raw data were searched using Spectronaut® software and data analyses were 166 performed with a combination of Perseus software, Python and R. B - Principal Component Analysis (PCA) 167 of the fibroblast validation cohort (N=24) relative to controls based on the differential abundance of whole 168 cell proteins calculated from t-test. C - Venn diagram showing the coverage of Mendeliome (v. 0.12869, 169 top panel) and Mitochondrial disease (v. 0.787, bottom panel) lists including green (diagnostic-grade) and 170 amber (borderline diagnostic-grade) genes retrieved from PanelApp Australia²⁷. D - Summary of the 171 genetic variant types analysed in the validation cohort (VC). E - Summary of the findings in the VC based 172 on protein identification and abundance. In 42% (10/24) of the cases the protein expected to be affected by 173 the genetic variant is not detected in the patient while it is detected in the controls. In 29% (7/24) of the 174 cases, the protein is not detected via quantitative proteomics, in 21% (5/24) of the cases, the protein is 175 decreased in abundance in the patient compared to the 5 controls, and in 4% (1/24) of the cases, the protein

is increased compared to the controls analysed. SNV = single nucleotide variant. F - Protein standard
 deviation from control median of the respective affected gene in controls (purple) and probands (red) in the
 validation cohort (VC). Standard deviation was calculated from the median control variance.

179

180 Mitochondrial content has previously been calculated in proteomics data using the mean 181 abundance of experimentally validated mitochondrial proteins in the MitoCarta 3.0 182 database^{28, 29}. We noticed that the mean abundance of mitochondrial proteins as a group varied between cell lines in our validation cohort (Supplementary Fig. 3A) but not control 183 individuals (Supplementary Fig. 3B). This phenomenon is typically taken into 184 185 consideration in enzymology analyses by expressing enzyme rates as citrate synthase 186 (CS) ratios to account for mitochondrial proliferation or cell/tissue variability^{10, 30}. CS enzyme activity in our validation cohort varied greatly (Supplementary Fig. 3A, upper 187 panel), consistent with altered mitochondrial content. Surprisingly, while CS activity did 188 have a weak positive correlation with the relative abundance of CS protein as detected 189 by proteomics (Supplementary Fig. 3C, left panel), it did not correlate with mitochondrial 190 191 content calculated from the abundance of mitochondrial proteins (Supplementary Fig. **3C, middle panel**). In line with this, CS protein abundance also did not correlate with 192 193 mitochondrial content calculated from proteomics data (Supplementary Fig. 3C, right panel). Since the nature of proteomics-based RCA is relative protein abundance, we 194 195 concluded that mean mitochondrial protein abundance is the appropriate metric to 196 normalise proteomics data. We built a differential mitochondrial abundance correction 197 step into our RCA calculations (see Materials and Methods for detailed information). 198 This correction is of benefit for cell lines that may have different mitochondrial content to 199 controls and corrects for mitochondrial content before calculating the relative abundance 200 of each complex.

201

We next sought to systematically benchmark our RCA analysis against clinical RCE. RCE was performed on 23 of the 24 fibroblast lines in the validation cohort, and was also performed on skeletal muscle (SKM) or lymphoblastoid cell lines (LCLs) for 17 of the 24 patients. Results are presented relative to CS (**Supplementary Table 2**) and the Bernier criteria³¹ were used to classify results. Fibroblast RCE detected a definite defect (<30%, major criterion) in the expected complex(es) for 19 of 24 fibroblast lines (79%) while three

[VC4 (NDUFS2), VC7 (NDUFAF1) and VC10 (NDUFB10)] had a probable defect (minor
criterion) and RCE did not detect a defect in VC19 (COX6B1) fibroblasts (Fig. 2A left
panel, Supplementary Table 2). When skeletal muscle or LCLs were also available,
RCE revealed a major defect in 9 of 17 of the analyses (53%), and a minor defect in four
(23%) while three were not deficient (18%) and one was not available (6%)(Fig. 2A, right
panel).

214

Relative complex abundance (RCA) analysis was performed incorporating the correction 215 for mitochondrial content (Supplementary Fig. 4) as described above. We classified a 216 217 major defect as an RCA abundance ≤65% relative to controls or ≤75% with absent detection of the protein of interest in the proband with >2 peptides detected in controls 218 219 while minor defects were classified by an RCA abundance of ≤75% relative to controls (Supplementary Table 2). Using these criteria, a major RCA defect was detected in 88% 220 of the cell lines in the validation cohort, a minor defect in a single case, VC19 (COX6B1), 221 222 and no defect was detected in three cell lines with mtDNA variants (Fig. 2B). Overall, 223 there is no strong correlation between RCE activity and an RCA value relative to control 224 (R=0.072, *p*=0.78) (**Fig. 2C**).

225

For isolated Complex I disorders, 83% (10/12 patients) had a complex I abundance lower 226 227 than 75% relative to controls analysed (p<0.0001). Two of the three Complex I-deficient 228 fibroblast lines harbouring missense mtDNA-encoded variants were refractory to RCA 229 analysis but diagnostic by RCE. mtDNA variant heteroplasmy in fibroblasts was 92% for 230 VC6 MT-ND1 and 71% for VC12 MT-ND5, highlighting a limitation of our approach in the 231 detection of some mtDNA-driven disorders. Importantly, in all 10 fibroblast lines where 232 RCA was diagnostic for a Complex I disorder, lower abundance (<65% relative to 233 controls) of Complexes III, IV and V were not noted (Supplementary Fig. 4). While Complex II was reduced to <75% in four of these. RCE similarly identified a probable 234 235 Complex II defect for one (FOXRED1), supporting the accuracy and specificity of RCA 236 analysis. In 7/7 individuals with isolated Complex II, III or IV disorders, the abundance of 237 the relevant complex was reduced to <75% controls (Fig. 2D) however t-test significance 238 varied, especially in CII and IV defects where the number of detected subunits was as

low as two. All were specific for the relevant isolated defect except for UQCRC2 where a Complex I abundance of 67% control (*p*<0.0001) was noted, as expected for Complex III disorders³².

242

243 For isolated disorders involving Complexes I-IV due to nuclear defects, we determine an 244 RCA value in fibroblasts of <65% controls to be diagnostic. The same threshold may also be applied to isolated disorders caused by pathogenic variants in mtDNA including those 245 leading to Complex V deficiency, however smaller reductions may not exclude 246 247 pathogenicity as seen in VC6 (*MT-ND1*), VC12 (*MT-ND5*) and VC20 (*MT-ATP6*) (Fig. **2D**). Interestingly, in the case of VC6 this was likely not due to heteroplasmy, which was 248 92% NC 012920.1(MT-ND1):m.3949C>T in fibroblasts. On the other hand, in VC12 the 249 250 NC_012920.1(*MT-ND5*):m.13513G>A variant found at 71% in fibroblasts, did not show the expected RCA defect while it satisfied the major criteria in RCE (Supplementary 251 252 **Table 2)**, suggesting impaired enzyme kinetics in the absence of a structural Complex I 253 defect. Finally, we found that defects directly impacting mitochondrial translation such as 254 MRPS34 fibroblasts presenting with a destabilised mitochondrial ribosome small subunit²⁵, *MT-TK* which encodes the mitochondrial lysine transfer RNA³³, *MTFMT* which 255 encodes the mitochondrial methionyl-tRNA formyltransferase³⁴, and FARS2 encoding 256 mitochondrial phenylalanyl-tRNA synthetase, led to combined Complex I and IV defects 257 258 that each met criteria of an RCA value <65% control (Fig. 2D), consistent with the major 259 criterion observed in RCE (Supplementary Table 2). Taken together, fibroblast RCA 260 detected an OXPHOS defect at <65% relative to controls in the expected complex(es) for 261 20 of 24 fibroblast lines tested (88%) (Fig. 2B). One fibroblast line, VC19 (COX6B1), had 262 an RCA of 71% for Complex IV relative to controls, which is in line with a previous report showing remaining assembled complex³⁵ and the peripheral position of the late 263 264 assembled COX6B1 subunit in the structure of Complex IV^{36, 37}. Three fibroblast lines where a definitive defect was not observed by RCA harboured variants in mtDNA, 265 266 suggesting that this class of variant may be more refractory to RCA analysis. Despite this, 267 proteomics-based RCA outperformed RCE in the detection of primary mitochondrial 268 disease. It is important to note here that the nature of proteomics as an untargeted 269 approach means that additional analyses can be performed from the same proteomic

data, such as reduced abundance of specific proteins encoded by the gene of interest
(Fig. 1E, F) and co-dependent proteins in structural modules (Supplementary Fig. 1B).
This is exemplified in the VC2 (*NDUFS6*) case where despite showing a Complex I
abundance of 74%, topographical mapping of Complex I subunit abundances against the
cryo-EM structure show specific reduction of the N-module of Complex I, providing strong
evidence in supporting disease causation.



276

277 Figure 2. Proteomics outperforms clinical respiratory chain enzymology in detection of 278 mitochondrial disorders A - (left) Summary of the RCE results in fibroblasts according to the Bernier criteria³¹. (right) Summary of the RCE results in tissues (skeletal muscle, skm or lymphoblastoid cell line, 279 280 LCL) according to the Bernier criteria³¹. **B** – Summary of the RCA results from quantitative proteomic data. 281 **C** – Pearson correlation between RCA results and Respiratory Chain Enzymology results for Complexes I, 282 III and IV. D - RCA results of OXPHOS complexes from the validation cohort showing the predicted affected 283 complexes for each cell line. CI-V = Complex I-V. Tr. = translation. Middle bar represents mean complex 284 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a 285 paired t-test between the individual protein means. **** = p<0.0001, *** = p<0.001, ** = p<0.01, * = p<0.01, * 286 ns = not significant, p>0.05.

After benchmarking quantitative proteomics and RCA analysis against the validation cohort, we applied our label-free DIA method to six undiagnosed cases where primary fibroblast or skeletal muscle were available for proteomic analysis.

291

292 UDP1 (*MT-ATP6*)

UDP1 (*MT-ATP6*) was a four-year-old child who had intrauterine growth retardation, 293 truncal hypotonia, microcephaly, global developmental delay, left ventricular 294 noncompaction and Wolff-Parkinson-White syndrome. Biochemically there was a 295 296 marginal elevation of blood lactate (2.8 mmol/L; normal range 0.7 - 2.0) and 3-297 methylglutaconic aciduria. variants Missense were identified in MT-ATP6 [NC 012920.1(MT-ATP6):m.8672T>C;p.(Leu49Pro)], a de novo variant with 81% 298 299 heteroplasmy in blood, and ATAD3A (heterozygous c.683C>T;p.Thr228Met) from WES plus mtDNA sequencing from blood and both classified as a VUS. Clinical RCE assays 300 301 typically do not include Complex V activity and proteomics was sought to provide functional evidence. Despite proteomic RCA analysis showing no reduction in abundance 302 303 of Complex V (104% relative to controls), there was a reduction in the number of Complex 304 V subunits identified from 13 to 10 compared to the diagnosed *MT-ATP6* patient as well as other cases in the same batch (Fig. 3A and Supplementary Fig. 4). The Complex V 305 306 subunits that are not detected in UDP1 (*MT-ATP6*) but are detected in VC20 (*MT-ATP6*) 307 are ATP5IF1, the ATPase inhibitor, and ATP5MD (ATP5MK/DAPIT) and ATP5MPL 308 (ATP5MJ/MP68/6.8PL), which like ATP6, are incorporated at a late stage in the assembly of Complex V^{36, 38}. The latter suggests a specific turnover of late stage assembled 309 310 subunits of Complex V below the limit of detection of proteomics in the proband, which 311 contributes to the unchanged Complex V levels seen in the RCA of UDP1 (*MT-ATP6*). 312 We processed the same data using q-value sparse run-wise imputation in the 313 Spectronaut[®] that allows for peptides that were identified in one sample to be imputed at 314 the limit of detection in samples where they were not detected. This allowed us to estimate the fold changes of ATP6 (MT-ATP6) and ATP5MPL proteins in UDP1 (MT-ATP6) and 315 316 correlate their reduced levels with VC20 (MT-ATP6) as well as confirming unchanged 317 levels of ATAD3A (Fig. 3B). Another data analysis strategy we explored for UDP1 (MT-318 ATP6) was the use of an *in-silico* library-free analysis including the protein sequence of

the ATAD3A variant p.Thr228Met. As expected, the peptide containing the methionine at position 228 was only detected in the patient (**Fig. 3C**) and present at ~43% of the abundance relative to the canonical peptide expressed from the other allele (**Supplementary Fig. 5A**). Taken together, these results suggest that the *MT-ATP6* p.Leu49Pro variant is the likely diagnosis for this case.

324

325 The lack of a Complex V defect in proteomics RCA analysis of both MT-ATP6 cases 326 (VC20 and UDP1) prompted us to analyse additional patients with known pathogenic 327 variants affecting Complex V. Supporting cohort probands SC1 and SC2 were two 328 unrelated infants presenting with lactic acidosis, cardiac abnormalities (persistent patent 329 ductus arteriosus, ventriculo-septal defect and cardiomyopathy), mild dysmorphic facial 330 features, hypospadias, hyperammonaemia and 3-methyl-glutaconic aciduria. Targeted gene sequencing based on this phenotype identified in both individuals a homozygous 331 332 intronic founder variant NM 017866.6(TMEM70):c.317-2A>G classified as Class 5/pathogenic, with several patients previously reported³⁹⁻⁴³. Skeletal muscle samples 333 were available for both cases and compared against three unrelated individuals using the 334 library-free DIA approach. Whole muscle proteomic analyses showed reduction of several 335 336 Complex V subunits in SC1 and SC2 respectively (Fig. 3D and E). RCA analyses quantified the relative abundance of Complex V at 19% and 20% (Fig. 3F and G), 337 338 demonstrating that defects in Complex V can be detected using RCA analysis. TMEM70 has also been implicated in Complex I assembly^{44, 45}, although no defects in Complex I 339 340 abundance were noted in these muscle samples.

341



342

Figure 3. Proteomics supports the diagnosis of patients with suspected mitochondrial disorders. A
 – Relative Complex Abundance (RCA) of Complex V subunits in undiagnosed patient UDP1 (*MT-ATP6*)

and diagnosed VC20 (*MT-ATP6*) patient. Middle bar represents mean complex abundance. Upper and

346 lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the 347 individual protein means. ns = not significant, p > 0.05. **B** – Correlation between log₂ fold-changes from 348 whole-cell proteins from run-wise imputed data between undiagnosed patient UDP1 (MT-ATP6) and 349 diagnosed patient VC20 (MT-ATP6) harbouring mutations in MT-ATP6 and controls showing reduced 350 abundance in late assembly proteins, MT-ATP6 and ATP5MPL, for both patients. C - Spectral intensity of 351 the peptide containing the ATAD3A p. Thr228Met variant detected in the UDP1 patient but not in controls. 352 **D** – Volcano plot of whole cell proteins from SC1 (*TMEM70*) whole-cell skeletal muscle compared to controls 353 (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent \pm 2-fold-354 change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent from a two-sample 355 t-test. E - Volcano plot of whole cell proteins from SC2 (TMEM70) whole-cell skeletal muscle compared to 356 controls (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent 357 \pm 2-fold-change equivalent and horizontal lines represent significance p-value \leq 0.05 equivalent from a two-358 sample t-test. F - Relative Complex Abundance (RCA) of OXPHOS subunits in undiagnosed patient SC1 359 (TMEM70). Middle bar represents mean complex abundance. Upper and lower bars represent 95% 360 confidence interval. Significance was calculated from a paired t-test between the individual protein means. 361 **** = p < 0.0001, *** = p < 0.001, * = p < 0.05, ns = not significant, p > 0.05. **G** – Relative Complex Abundance 362 (RCA) of OXPHOS subunits in undiagnosed patient SC2 (TMEM70). Middle bar represents mean complex 363 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a 364 paired t-test between the individual protein means. **** = p<0.0001, *** = p<0.001, ** = p<0.001, * = p<0.001, ** = 365 H - Volcano plot of whole cell proteins from UDP4 (CCDC47) fibroblasts compared to controls showing 366 reduced abundance of CCDC47. No significant changes to Complex V proteins (orange). Vertical lines 367 represent \pm 2-fold-change equivalent and horizontal lines represent significance p-value \leq 0.05 equivalent 368 from a two-sample t-test. I - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP4 369 (CCDC47) fibroblasts compared to controls. * = p < 0.05, ns = not significant, p > 0.05. J – Volcano plot of 370 whole cell proteins from UDP5 (NDUFA10) fibroblasts compared to controls showing reduced abundance 371 of NDUFA10 and other structural subunits of Complex I. Vertical lines represent ± 2-fold-change equivalent 372 and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = Complex I subunits. K -373 Relative Complex Abundance (RCA) of OXPHOS complexes from UDP5 (NDUFA10) fibroblasts compared 374 to controls (N=4) showing isolated Complex I defect. Middle bar represents mean complex abundance. 375 Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test 376 between the individual protein means. **** = p<0.0001, * = p<0.05, ns = not significant, p>0.05. L – 377 NDUFA10 and HIBCH protein abundance from two-sample t-test in SC3, a confirmed HIBCH proband and 378 UDP5 (NDUFA10) whole-cell fibroblasts compared to controls showing an approximate half reduction in 379 HIBCH levels in UDP5 (NDUFA10, HIBCH carrier) compared to SC3 and unchanged NDUFA10 levels in 380 SC3. M - Timeline for the rapid proteomics from live fibroblast sample receipt to results for UDP5 381 (NDUFA10) case achieved in less than 5 business days.

382

383 UDP4 (CCDC47)

UDP4 (*CCDC47*) was born to consanguineous parents, presenting with intrauterine growth restriction, severe failure to thrive, short stature, hypotonia, marked developmental delay, mildly dysmorphic features, severe pruritus woolly hair and increased plasma bile acids (224 μmol/L; normal range <7), Ricketts and decreased mitochondrial CIII activity in liver and muscle⁴⁶. WES performed on DNA extracted from fibroblasts and analysed using a mitochondrial disease gene panel identified single heterozygous missense

390 variants NM_001358921.2(COQ2):c.460G>C; p.(Gly154Arg) and 391 NM 020312.4(COQ9):c.826C>T p.(Arg276Trp). Suspecting a compound oligogenic 392 mechanism impacting Coenzyme Q biosynthesis, RCA analysis was performed on 393 fibroblast cells. No abundance changes to COQ9 or respiratory chain complexes I-IV 394 were identified, although an abundance of 84% in Complex V was noted (Fig. 3H and I). 395 This reduction was regarded as not biologically significant as no rare variants in Complex V related genes were flagged from sequencing data. Transcriptomic analysis performed 396 in RNA extracted from skeletal muscle showed a reduced abundance of CCDC47 397 398 transcript (Supplementary Fig. 5B). Re-analysis of proteomics data was sought to 399 provide functional evidence to support the transcriptomic findings, which confirmed a 400 reduction in the abundance of CCDC47 in primary fibroblasts from imputed data (Fig. 3H). 401 Re-analysis of sequencing data identified а homozygous variant NM_020198.3(*CCDC47*):c.431C>G;p.(Thr144Asn). SpliceAl predicted (δ score 0.964) 402 the activation of a donor-splice site five nucleotides upstream of this variant, and PCR 403 404 analysis of the muscle cDNA showed the presence of both the missense transcript and a second shorter one, missing 121 bp from the 3' end of exon 4 resulting in a loss-of-405 406 function type transcript p.(Val143Glyfs*15) (Supplementary Fig. 5C). This variant is not 407 observed in the gnomAD population database nor any clinical cases previously but is predicted to be classified as likely pathogenic/Class 4, supported by the observed splicing 408 409 defect, as well as reduced abundance in CCDC47 transcript and CCDC47 protein levels. 410 CCDC47 has been previously linked to Trichohepatoneurodevelopmental Syndrome⁴⁷ (MIM 618268) which presents an overlapping phenotype to UDP4 (CCDC47). The 411 412 observed reduction in CCDC47 transcripts due to incorrect splicing is in keeping with previously reported patients, all of whom harbour loss-of-function variants^{47, 48}. 413

414

415 UDP5 (NDUFA10)

416 UDP5 presented with nystagmus, hypotonia, vomiting and weight loss at 20 weeks of age. 417 She had lactic acidosis, concentric left ventricular hypertrophy with 48% ejection fraction, 418 T2 hyperintense lesions in the substantia nigra and passed away at 24 weeks of age. 419 Targeted exome sequencing analysis flagged candidate variants 420 NM 004544.4(*NDUFA10*):c.914T>C; p.(Leu305Pro) homozygous VUS/Class 3.

421 NM 014362.4(*HIBCH*):c.891+1G>A, heterozygous likely pathogenic/Class 4 and NM 018292.5(QRSL1):c.22G>C, p.(Glu8GIn) heterozygous VUS/Class 3. Fibroblast 422 423 proteomics detected NDUFA10 and HIBCH below 2-fold-change (representing >50% reduction) in the patient relative to controls (Fig. 3J and Supplementary Figure 5D). 424 425 QRSL1 level was slightly increased but not significant, which led us to further investigate 426 NDUFA10 and HIBCH leads. NDUFA10 is a structural subunit of Complex I and additional 427 functional evidence for pathogenicity could be drawn from reduced abundance of other 428 Complex I subunits, with RCA analysis guantifying Complex I abundance at 43% in UDP5 429 (*NDUFA10*) compared to controls, meeting the criteria for a major defect (**Fig. 3K**). We 430 further assessed whether the levels of HIBCH protein were compatible with a carrier 431 (heterozygous) state by analyzing fibroblasts from an unrelated patient (SC3) diagnosed 432 with bi-allelic pathogenic variants: NM_014362.4(*HIBCH*):c.891+1G>A & NM_014362.4(*HIBCH*):c.470G>A; p.(Arg157Gln). Proteomic results show that HIBCH 433 434 protein in SC3 (HIBCH) is almost two times less abundant than in UDP5 (NDUFA10) (Fig. 435 **3L**, left panel) while the levels of NDUFA10 protein were unchanged in SC3 (*HIBCH*), 436 suggesting that a reduction in NDUFA10 is not a secondary defect from a primary HIBCH defect (Fig. 3L right panel). The lack of any decrease in Complex I in SC3 (*HIBCH*) 437 438 suggests that the phenotype in UDP5 (*NDUFA10*) is likely to have arisen from the 439 NDUFA10 variant while the HIBCH variant is expressed as a carrier and further 440 investigation for a second missed variant in *HIBCH* was not undertaken. UDP5 was the 441 first child of non-consanguineous parents of Māori ethnicity. The mother was 6 weeks pregnant with a second child at the time of analysis and the family sought prenatal genetic 442 443 testing (PGT). With this in mind, we prioritised sample processing and analysis, and were 444 able to return results in less than 4 days from receipt of fibroblasts (Fig. 3M) with the 445 results sufficient to support the upgrade of the NDUFA10 variant c.914T>C; 446 p.(Leu305Pro) to likely pathogenic/Class 4. This facilitated PGT, which confirmed absence of the NDUFA10 variant, allowing continuation of the pregnancy and delivery of 447 448 a healthy child who, at the time of writing, is 15-months old.

449

The rapid turnaround time (TAT) in this case was only possible as fibroblasts from UDP5 were available for analysis at the time of proteomics testing. Establishing and culturing a

452 new fibroblast line typically takes up to ~ 2 months and requires a skin biopsy⁴⁹ which is 453 increasingly considered invasive and can potentially delay a diagnosis. We sought to 454 explore the feasibility of rapid proteomics-based testing for suspected mitochondrial disorders using peripheral blood mononuclear cells (PBMCs), which can be readily 455 456 obtained from whole blood and have been used in various diagnostic functional testing 457 approaches previously. To test the applicability of PBMCs in proteomic testing we first generated a fractionated spectral library and compared it against the fibroblast spectral 458 library and coverage of Mendeliome proteins (**Fig. 4A**). The PBMC library was generated 459 from peptides of 39 normal individuals aged 0-17 years of age and can be used to 460 461 confidently identify 8,016 gene products, including 52% of known Mendeliome genes²⁷. In comparison, our fibroblast spectral library covers 8,305 genes and 55% of the 462 463 Mendeliome. We performed a Principal Component Analysis (PCA) of whole-cell proteins in the 37 PBMC samples showing that over 99% of the proteins are tightly clustered at 464 the whole-cell level and over 97% at the mitochondrial level (Fig. 4B). 465

466

467 Next, we validated the use of PBMCs against fibroblasts by analysing both sample types from a diagnosed patient with pathogenic variants in MRPL50 (Twin 2 in ²¹, SC4 and 468 SC5). MRPL50 is a structural subunit of the mitoribosome⁵⁰ and defects in this subunit 469 470 lead to impaired assembly of the large mitoribosomal subunit (mtLSU)²¹. We performed 471 a correlation of the log₂ fold-change levels of mitochondrial proteins identified in both 472 samples relative to controls which showed reduced abundance of multiple proteins 473 belonging to the mtLSU in both sample types (Fig. 4C). RCA quantified the abundance 474 of the mtLSU in 63% and 48% in PBMCs and fibroblasts respectively (Supplementary 475 Fig. 5E).



476

Figure 4. Utility of ultra-rapid proteomics supports the diagnosis of critically ill infants with
 suspected mitochondrial disorders A – Venn diagram showing the coverage of Mendeliome genes
 (PanelApp Australia Green and Amber entries, 4,264 genes) in the fibroblast spectral library (55% of

480 Mendeliome list of genes) and PBMC library (52% of Mendeliome list of genes). B - Principal Component 481 Analysis (PCA) of the pilot PBMC normative data (N=37) for whole-cell proteins (top panel) and 482 MitoCarta3.0 proteins (lower panel). C - Scatter plot showing the correlation between PBMC (SC4) and 483 fibroblast (SC5) samples based on log₂ fold-changes from whole-cell proteins in a diagnosed patient with 484 variants in MRPL50 relative to controls²¹ showing reduced abundance of the proteins belonging to the large 485 subunits of the mitochondrial ribosome (mtLSU; purple), mtSSU = mitoribosome small subunit (orange). 486 D - Volcano plot of whole cell proteins from UDP6 (NDUFA13) PBMCs compared to controls (N=5) showing 487 reduced abundance of NDUFA13 (orange dot) and other structural subunits of Complex I. Vertical lines 488 represent \pm 2-fold-change equivalent and horizontal lines represent significance p-value \leq 0.05 equivalent. 489 Blue = Complex I subunits. E - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP6 490 (NDUFA13) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar 491 represents mean complex abundance. Upper and lower bars represent 95% confidence interval. 492 Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, * = 493 p < 0.05, ns = not significant, p > 0.05. **F** – Protein range for NDUFA13 in PBMCs in UDP6 (*NDUFA13*, red 494 dot) and controls (N=5, purple dots) showing standard deviation of -12.2 from the control median. G -495 Volcano plot of whole cell proteins from UDP7 (NDUFAF6) PBMCs compared to controls (N=5) showing 496 reduced abundance of NDUFS8 and other structural subunits of Complex I. Vertical lines represent \pm 2-497 fold-change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = 498 Complex I subunits. H - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP7 499 (NDUFAF6) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar 500 represents mean complex abundance. Upper and lower bars represent 95% confidence interval. 501 Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, ** 502 = p<0.01, ns = not significant, p>0.05. I – Timeline for ultra-rapid proteomics from PBMC sample receipt to 503 results for UDP8 (NDUFS8) case achieved in less than 3 business days. J - Volcano plot of whole cell 504 proteins from UDP7 (NDUFS8) PBMCs compared to controls (N=5) showing reduced abundance of 505 NDUFS8 protein (orange dot) and other structural subunits of Complex I. Vertical lines represent ±2-fold-506 change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = Complex I 507 subunits. K - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP8 (NDUFS8) PBMCs 508 compared to controls (N=5) showing isolated Complex I defect. Middle bar represents mean complex 509 abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a 510 paired t-test between the individual protein means. **** = p<0.0001, ** = p<0.01, * = p<0.05, ns = not 511 significant, p>0.05. L - Protein range for NDUFS8 in PBMCs in UDP8 (NDUFS8, red dot) and controls (N=5, 512 purple dots) showing standard deviation of -9.3 from the control median.

513

514 UDP6 (*NDUFA13*)

UDP6 (NDUFA13) presented at 2 years of age with chronic ataxia. She was the first child 515 516 to non-consanguineous healthy parents from Iran and had a healthy 2-month-old brother. 517 There was no family history of any neurological issues. She presented with chronic, stable 518 ataxia, having been unsteady and falling frequently since she started walking at 14 519 months of age. She had mild fine motor delay and a tremor. Her social, language, and 520 cognitive development was age appropriate. On examination, UDP6 (NDUFA13) had 521 normal growth parameters and was not dysmorphic. She had mild gait ataxia with a broad 522 base. Her tone, power and reflexes were normal in upper and lower limbs bilaterally.

523 Ophthalmology examination was unremarkable. Magnetic resonance imaging (MRI) of 524 brain showed bilateral symmetrical T2/FLAIR hyperintensity of the cerebral peduncles of 525 the midbrain (and possibly the substantia nigra) and two symmetrical foci of high signal in the dorsal medulla with diffusion-weighted imaging (DWI) restriction. There were no 526 527 basal ganglia or thalamic abnormalities. This was suggestive of a mitochondrial disorder. 528 Serum blood lactate was elevated 2.4 (RR 1.0-1.8). Other metabolic investigations were 529 normal. Audiology assessments and echocardiogram were normal. At 4 years of age, she has ongoing mild ataxia that improved with physiotherapy and was no longer falling. She 530 531 has recently had deterioration in her vision and been diagnosed with optic neuropathy. 532 Trio identified exome sequencing compound heterozygous variants 533 NM 015965.7(*NDUFA13*):c.170G>A; p.(Arg57His) likely pathogenic/Class 4 and 534 NM_015965.7(NDUFA13):c.187G>A; p.(Glu63Lys) VUS/Class 3. Proteomics was sought to provide functional evidence for the VUS/Class 3 variant and blood was collected for 535 536 PBMC isolation as fibroblasts were not available at the time of analysis. Five unrelated 537 PBMCs from age-matched normal donors were used as controls. A volcano plot showed 538 reduction of NDUFA13 protein and several other Complex I subunits in UDP6 (NDUFA13) 539 (Fig. 4D) and RCA quantified the isolated Complex I defect at 47% control satisfying the 540 criteria for a major defect (Fig. 4E). Analysis of the level of the NDUFA13 protein in the proband demonstrated a residual abundance of 39%, which corresponds to greater than 541 542 12 standard deviations below the control median (Fig. 4F). Proteomics data were 543 subsequently functional evidence used as to upgrade the 544 NM 015965.7(NDUFA13):c.187G>A;p.(Glu63Lys) variant to likely pathogenic/Class 4.

545

546 UDP7 (NDUFAF6)

547 UDP7 (*NDUFAF6*) was referred to the study at five months of age with asymmetric early 548 onset growth restriction, central hypotonia, proximal renal tubular dysfunction, macrocytic 549 anaemia, severe exocrine pancreatic insufficiency, liver dysfunction with cholestasis and 550 mild persistent elevated lactate in CSF and blood. MRI showed symmetrical diffusion 551 abnormality involving corticospinal tract, areas of brainstem and medial cerebellar 552 hemisphere. He died at seven months of age due to progressive bulbar dysfunction with 553 a probable clinical diagnosis of Leigh syndrome. Clinical trio WES identified a single

medRxiv preprint doi: https://doi.org/10.1101/2024.08.06.24311318; this version posted August 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

554 pathogenic (Class 5) heterozygous NM 000262.3(NAGA):c.973G>A; p.(Glu325Lys) 555 variant. and two in trans variants in NDUFAF6. а frameshift 556 NM_152416.4(NDUFAF6):c.267delT, p.(Tyr323llefs*18) variant and a deep intronic NM_152416.4(NDUFAF6):c.298-768T>C, both classified as VUS/Class 3. 557 variant. 558 PBMCs were the sample of choice due to lower invasiveness and potential for fast 559 turnaround. Whole-cell proteomics identified no changes in the abundance of NAGA 560 protein relative controls (Fig **4G**). NAGA encodes the alpha-Nto 561 acetylgalactosaminidase, a lysosomal enzyme whose deficiency causes a rare 562 autosomal recessive lysosomal storage disorder. Previous reports of NAGA-deficiency 563 show heterogenous presentations ranging from infantile-onset neuroaxonal dystrophy (Schindler disease type I, MIM 609241) to an adult-onset disorder characterised by 564 565 angiokeratoma corporis diffusum and mild intellectual impairment (Schindler disease type II, also known as Kanzaki disease MIM 609242)⁵¹. In addition to the proteomic studies, 566 567 UDP7 (NDUFAF6) did not appear to have clinical features consistent with NAGA-568 deficiency, and infants with this condition typically develop normally until about a year old. 569 We then turned our investigations to NDUFAF6 (C8orf38) which encodes an assembly factor involved in biogenesis of the core peripheral arm subunit NDUFS8 of Complex I⁵² 570 571 and has previously been associated with the stability of the ND1 module of Complex I^{53} , ⁵⁴. Previous reported cases of pathogenic variants in *NDUFAF6* present with a range of 572 573 symptoms, including Leigh syndrome and the Acadian variant of Fanconi syndrome 5 (proximal renal tubular dysfunction) (FRTS5, MIM 618913)⁵³⁻⁵⁷. UDP7 (NDUFAF6) had 574 575 clinical features consistent with Leigh syndrome, and while the aetiology of his liver 576 dysfunction and severe exocrine pancreatic insufficiency was somewhat less clear, both 577 would broadly fit with a mitochondrial cytopathy noting Complex I deficiencies often do 578 not correlate perfectly with а single clinical subdivision. The 579 NM_152416.4(*NDUFAF6*):c.298-768T>C variant has been reported as likely pathogenic previously, specifically in relation to the FRTS5 phenotype⁵⁶. A volcano plot from whole-580 581 cell PBMC proteomics data showed reduction in the abundance of several subunits of 582 Complex I in UDP7 (*NDUFAF6*), including NDUFS8, (Fig. 4G) with RCA analysis quantifying the isolated Complex I defect with a major defect of 34% relative to controls 583 584 (Fig. 4H). Functional proteomic data and phenotype match support NDUFAF6 as being

the causative gene for this clinical case, and the VUS/Class 3 variants are in the processof re-curation at the time of writing.

587

588 UDP8 (NDUFS8)

589 UDP8 (NDUFS8) was a neonate admitted to hospital presenting with persistent lactic 590 acidemia, hypertrophic cardiomyopathy, left pulmonary artery stenosis, thickened pulmonary valve, hypotonia and microcephaly with progressive deterioration from 4 weeks 591 592 of age, succumbing at 5 weeks of age. Brain MRI showed abnormalities in the corpus 593 callosum and diffuse increased signal throughout the supratentorial white matter with 594 small foci of gliosis in the peritrigonal regions. Ultra-rapid trio WGS identified a 595 homozygous intronic variant NM 002496.4(NDUFS8):c.501+5G>A with biparental 596 inheritance. Due to the critical deteriorating condition, blood was collected from the proband and subjected to ultra-rapid proteomics. Five unrelated age-matched controls 597 598 were used for comparison and the complete analysis was performed with a 54-hour 599 turnaround time (TAT) from PBMC sample reception to the reporting of results to the 600 clinical team (Fig. 41). Whole-cell proteomic analysis of PBMCs showed significant 601 reduction of several Complex I subunits, including NDUFS8 (Fig. 4J) and RCA analysis 602 showed an isolated Complex I defect with a major defect of 22% relative to controls (Fig. 603 **4K**). Residual abundance of the NDUFS8 protein in the proband was quantified at 20%, 604 representing over 9 standard deviations below the control median (Fig. 4L). The strong phenotype match together with functional evidence from proteomics support disease 605 606 causation due to variants in NDUFS8 and leading to variant upgrade to likely 607 pathogenic/Class 4.

608

609 Discussion

The estimated prevalence of rare disease in the population is in the range of 3.5-6%, equivalent to 263-446 million individuals worldwide⁵⁸. There are over 7,000 different rare diseases known, with a current diagnostic yield of ~35-70% from WES or WGS¹⁻⁵. Mitochondrial disease is a group of rare diseases caused by variants in over 300 known genes^{6, 16}, where RCE has been historically performed to confirm a specific OXPHOS defect in the functional validation of variant pathogenicity¹⁶.

616

617 We have previously used an approach we term relative complex abundance (RCA) where 618 proteomics data are used to quantify the residual abundance of OXPHOS complexes in 619 clinical samples from individuals suspected of mitochondrial disease. We have shown 620 that RCA acts as an effective proxy for clinically accredited RCE, including when appropriate samples have not been available^{20-22, 24, 25, 59-61}. In an RCA analysis, the 621 622 abundance of a complex in a sample is calculated from the mean of each individual subunit abundance detected by more than two peptides across each complex. The power 623 624 of RCA analysis relies on the quantification of multiple peptides per protein in a complex 625 with a high degree of subunit stability co-dependence, as we and others have previously shown for Complex I, III, IV, the mitoribosome^{11, 17, 20-22, 25, 59, 60, 62, 63} and non-mitochondrial 626 complexes such as the exocyst and nuclear pore complexes^{64, 65}. RCE, on the other hand, 627 typically relies on enzyme rate estimates determined in several replicates of patient 628 629 samples and compared against age-matched controls. In some instances, we have found 630 RCA demonstrated higher sensitivity by detecting a specific OXPHOS defect where RCE was inconclusive^{20, 22}. RCA can also show higher specificity for use in functional validation 631 632 of variant pathogenicity by detecting reduction of specific parts of the complex (e.g. loss of subunits in the catalytic Complex I N-module in VC1-NDUFAF2 and VC2-NDUFS6), 633 implicating only the 10 N-module subunits as candidate genes compared with loss of 634 635 Complex I RCE potentially being caused by variants in any of more than 50 genes encoding Complex I subunits and assembly factors^{26, 66}. In other cases, some variants 636 637 encoded by the mtDNA resulted in no defect on RCA analysis despite over 70% and 90% 638 heteroplasmy levels in fibroblasts. This suggests that some mtDNA variants can be 639 refractive to RCA analysis due to an enzymatic and not a structural defect, where RCE 640 might be an appropriate test to provide functional evidence. In terms of variant type, 641 mitochondrial DNA variants account for only 0.54% of rare diseases while autosomal recessive variants account for over 41%⁶⁷ and are more likely to result in a loss-of-642 643 function protein⁶⁸, which can be detected via quantitative proteomics.

644

645 RCE is typically performed on a tissue biopsy sample (e.g. skeletal muscle, liver) or 646 primary cultured cells (e.g. fibroblasts). Establishing and growing primary fibroblasts from

647 skin biopsies to a sufficient volume of cells for RCE analysis involves weeks to months of 648 cell culture⁴⁹, and, in some cases, tissue specificity results in only mild or undetectable 649 defects as measured by RCE¹⁰. Here we have demonstrated the feasibility of using PBMCs in diagnostic proteomics testing. In our hands, sufficient PBMCs for these 650 651 analyses can be readily obtained from as a little as 1 ml of whole blood and the process 652 from PBMC isolation to data acquisition performed in less than 48 hours. Together these properties and the results presented in this study demonstrate that PBMCs can be 653 combined with our ultra-rapid proteomics pipeline for functional validation of variants 654 655 causing defects in the mitochondrial OXPHOS system and the mitoribosome.

656

The untargeted nature of quantitative proteomics also allows this technique to be applied 657 658 beyond mitochondrial disease, as we have shown here for a mitochondrial disease phenocopy (UDP4; CCDC47) and elsewhere for nuclear pore, neuronal exocytic vesicle 659 trafficking and rigid spine disorders^{64, 65, 69}. Over 50% of known disease-associated 660 genes²⁷ are routinely detected by our quantitative proteomics pipeline in PBMCs or 661 662 fibroblasts, and over 45% of all disease genes listed in OMIM are part of a protein complex¹⁶. This means that pathogenic variants in one of these genes can lead to 663 664 reduction of the protein of interest, which in some cases will result in downstream complex 665 reduction as an additional layer of functional evidence to support variant upgrade. In 666 terms of variant type, we show that quantitative proteomics can provide functional evidence for a wide range of genetic variants including CNV⁶², splice site and deep 667 intronic^{20, 22}, and missense variants²¹. Missense variants are the most common type of 668 669 variant accounting for 60% of pathogenic variants associated with autosomal recessive disorders¹⁸ and are usually refractory to transcriptomic analysis. For some cases, 670 671 proteomics can also provide supportive functional evidence supportive when the protein 672 encoded by the candidate gene is not detectable, either due to protein abundance being 673 below the limit of detection or for genes encoding tRNAs, as seen in VC22 (MT-TK), 674 further expanding the potential application of proteomics in rare disease diagnosis.

675

676 A genomics-first approach to rare disease diagnosis has markedly increased diagnostic 677 rates and, in the case of rapid and ultra-rapid genomic testing, shortened diagnostic

odysseys to days instead of months^{65, 70-72}. In the case of mitochondrial and many other rare diseases, diagnoses are often now achieved using just a blood sample, sparing many patients from an invasive biopsy of muscle or other tissues. As a result, diagnostic centres such as ours now receive a third or less of the number of samples for RCE testing than received 10 years ago. This provides an incentive for untargeted functional tests, such as RNA sequencing and proteomics, that could be financially viable and widely available in a pathology-certified context.

685

686 This study also highlights the limitations of quantitative proteomics in detecting 687 abundance changes in variants leading to catalytic defects and some mtDNA-encoded 688 variants in fibroblasts. Moreover, the detection of proteins is related to the limit of 689 detection as determined by the liquid chromatography, mass-spectrometry instrumentation, and data acquisition methods used. However, recent advances in mass-690 691 spectrometry instrumentation including development of the asymmetric track lossless 692 (Astral) analyzer offer further improvements in sensitivity and greatly reduced run times⁷³. Quantitative proteomics thus offers a further paradigm shift by providing functional 693 694 evidence for variants in thousands of genes in a single test. This driver will facilitate the 695 translation of proteomics testing for rare diseases into certified pathology laboratories. 696 Clinically delivered proteomics can potentially replace hundreds of tests targeted to 697 specific diseases, which are usually restricted to research settings and carry less weight 698 in the upgrade of variants. Our study also demonstrates that proteomics can be delivered 699 alongside ultra-rapid genomic sequencing approaches to provide functional data in a 700 clinically relevant timeline.

701

702 Materials and Methods

703 Ethics statement

This study was conducted in accordance with the revised Declaration of Helsinki and 704 705 following the Australian National Health and Medical Research Council statement of 706 ethical conduct in research involving humans. Samples were obtained after receiving 707 written, informed consent for diagnostic or research investigations from the respective 708 responsible ethics institutional review boards. HREC/RCH/34228, human 709 HREC/RCH/34183, HREC/89419/RCHM-2022 and HREC/82160/RCHM-2022 were

approved by the Royal Children's Hospital, Melbourne, Ethics in Human Research
Committee. HREC/16/MH/251 was approved by the Melbourne Health Human Research
Ethics Committee. The REC reference 2002/205 by the Newcastle and North Tyneside

- 713 Local Research Ethics Committee.
- 714

715 Genomic investigations

716 Genomic investigations resulting in diagnosis of patients within the validation cohort (VC) 717 are described in the publications indicated by PMID within **Supplementary Table 1**, with 718 the exceptions of VC13 (SDHAF1), VC15 (UQCRC2) and VC24 (FARS2) which are as 719 follows: Individual VC13 (SDHAF1) underwent clinical singleton WES through Baylor 720 Genetics as previously described⁷⁴. For individual VC15 (UQCRC2), homozygosity 721 mapping from Illumina HumanCytoSNP-12 v2.1 array data identified substantial long 722 contiguous stretches of homozygosity (LCSH) accounting for ~3.7% of the genome. Due 723 to the observed complex III RCE defect in this patient, candidate gene sequencing of 724 exons using genomic DNA through PCR and sanger sequencing was performed on 725 complex III-related genes UQCC1 and UQCRC2 which lay within these regions of LCSH 726 (primers available upon request). Blood DNA for individual VC24 (FARS2) underwent 727 clinical singleton WES testing through the Victorian Clinical Genetics Service (VCGS) as 728 previously described⁷⁵. mtDNAseq was also used to quantify mtDNA variant 729 heteroplasmy levels for individuals VC6 (*MT-ND1*) and VC12 (*MT-ND5*) as previously 730 described⁷⁵. Individuals within the undiagnosed patient (UDP) cohort were investigated 731 as follow: blood DNA from UDP1 (MT-ATP6) underwent WES with mitochondrial DNA 732 sequencing (mtDNAseq) as part of the Australian Genomics Mitochondrial Flagship as 733 described⁷⁵. For individual UDP4 (CCDC47), sequencing and analysis was performed as 734 previously described²⁵. Individual UDP5 (*NDUFA10*) had the Comprehensive Metabolism 735 Panel performed by Blueprint Genetics. Individuals UDP6 (NDUFA13) and UDP7 736 (NDUFAF6) both underwent clinical trio WES through the Victorian Clinical Genetics 737 Service (VCGS)⁷⁵. UDP8 (*NDUFS8*) had acute-care rapid trio WGS and analysis at the 738 VCGS as previously published⁶⁵.

739

740 Respiratory chain enzymology

Respiratory chain enzyme activities in fibroblasts and skeletal muscle were measured by spectrophotometry as described¹⁰. Complex I (CI) was measured as rotenone-sensitive NADH:coenzyme Q_1 oxidoreductase, Complex II (CII) as succinate:coenzyme Q_1 oxidoreductase, Complex III (CIII) as decylbenzylquinol:cytochrome *c* reductase, and Complex IV (CIV) as cytochrome *c* oxidase. Citrate synthase (CS) was measured as

production of coenzyme A (CoA.SH) from oxaloacetate using the thiol reagent 5,5'-dithio bis-(2-nitobenzoic acid). Enzyme activities were calculated as initial rates (CI, CII, and
 CS) or as first-order rate constants (CIII and CIV)¹⁰.

749

750 Cell Culture Conditions

Fibroblast and HEK293T cell lines were cultured in Dulbecco's Modified Eagle Medium
(DMEM) High Glucose, Sodium Pyruvate and Glutamine (Sigma-Aldrich) supplemented
with 10% (v/v) Fetal Calf Serum (FCS; CellSera), 100 U/mL Penicillin-Streptomycin
(Gibco) and 50 µg/mL Uridine. Cells were maintained at 37°C with 5% CO2.

755

756 Generation of knockout lines

757 The NDUFS2^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding the quide RNA 5'-TGAGGGCTTTGTGCGGCTTCCGG-3' cloned into the pSpCas9-2A-GFP 758 vector ²⁶. The CRISPR was transfected into HEK293T cells and single cells were obtained 759 760 by Fluorescence-activated cell sorting at the Monash Flow Cytometry Platform (Flowcore). 761 Singe cell populations were screened by loss of cell viability on galactose-containing 762 DMEM and subsequently validated by the loss of protein by western blotting and indel 763 sequencing, which identified two deletions c.[18_36del] and c.[17_42del] Supplementary 764 table 1). The UQCRC2^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding 765 RNA 5'-CACCGGTACTTACACATCACCCCGC the quide designed using the 766 CHOPCHOP tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously 767 described²⁶. The plasmids were validated by sequencing, and then transfected into target 768 cell lines using Lipofectamine[™] 3000 Transfection Reagent (Thermo Fischer Scientific) 769 according to manufacturer's guidelines. Single cells expressing GFP were isolated on a 770 FACS Aria Fusion (BD Biosciences) cell sorter and clonal populations were subsequently 771 screened for relevant gene knockouts using SDS-PAGE and immunoblotting and indel 772 sequencing, which identified two deletions c.[9141 9199del] and [9146 9167del] (Supplementary table 1). The SURF1^{KO} cell line was generated using a CRISPIR/Cas9 773 774 system with the HEK293T parental cell line. Two guide RNAs targeting the 5'UTR and 775 exon 2 regions of SURF1 were cloned into individual pSpCas9-2A-GFP vectors (Addgene, 776 plasmid 48138¹⁸). Both constructs were transfected simultaneously into HEK293T cells using Lipofectamine 3000 (Thermo Fisher Scientific), according to the manufacturer's 777 instructions. Verification of successful HEK293T SURF1^{KO} was performed via three 778 779 primer screening PCR were used to amplify incorporated indels via PCR and by SDS-780 PAGE immunoblotting. The product of external Primers (outside the double CRISPR 781 target sites) underwent M13 primer Sanger Sequencing of alleles, using the Topo[™] TA

782 Cloning Kit (Thermo Fisher Scientific) as per the manufacturer's instructions. Sequencing 783 identified two deletions [c.18 219del] and [c.18 221delinCG] (Supplementary table 1). The ATP5PD^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding the 784 785 guide RNA 5'-CACCGCCTTTCCTTGTGGGCAGGT designed using the CHOPCHOP 786 tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously described²⁶. The 787 plasmids were validated by sequencing, and then transfected into target cell lines using 788 Lipofectamine[™] 3000 Transfection Reagent (Thermo Fischer Scientific) according to 789 manufacturer's guidelines. Single cells expressing GFP were isolated on a FACS Aria 790 Fusion (BD Biosciences) cell sorter and clonal populations were subsequently screened 791 for relevant gene knockouts using indel sequencing, which identified a single deletion 792 c.[33481insT] (Supplementary table 1).

793

794 PBMC isolation from whole blood

795 Neonatal blood samples were collected from healthy neonates following routine 796 intramuscular administration of Vitamin K. For older infants and children ages 30 days to 797 18 years, venous blood samples were obtained from hospital outpatients undergoing 798 minor elective day surgery. An outline of the study protocol and complete detail of 799 participant recruitment, inclusion and exclusion criteria and sample collection are 800 described in our previously published HAPPI Kids study protocol⁷⁶. PBMCs were isolated 801 from fresh blood samples of the 37 HAPPI Kids controls using Ficoll[®]-Pague Plus (GE 802 Healthcare Life Sciences) according to the instructions of the manufacturer with manual 803 removal of the PBMC layer using a Pasteur pipette. For the UDP6 (NDUFA13), UDP7 804 (NDUFAF6) and UDP8 (NDUFS8) probands, PBMC isolation using Ficoll[®]-Pague Plus performed in SepMate[™] tubes (STEMCELL Technologies), 805 was based on 806 manufacturer's protocols with moderate braking applied for both washes, and a reduction 807 in centrifugation speed and duration to 200 g for five minutes for the second wash.

808

809 Data-Independent Acquisition Mass Spectrometry of Fibroblast, HEK293T and PBMCs

- 810 Cohorts and Data Analysis
- 811
- 812 Spectral Library Sample Preparation

A HEK293T spectral library was generated from both whole cell and mitochondrial HEK293T samples to search data-independent acquisition (DIA) HEK293T knockout cell lines. A total of 100 µg of mitochondrial sample isolated from wildtype HEK293T cells underwent carbonate extraction at pH 11.5 to separate soluble and integral mitochondrial proteins, as previously described⁷⁷. The resulting pellet and supernatant samples, as well

818 as 25 µg whole cell HEK293T sample, were solubilized in lysis buffer for a final 819 composition of 5% SDS and 50 mM Triethylammonium bicarbonate (TEAB) pH 8.5. The lysed whole cell, mitochondrial pellet and supernatant samples were processed using S-820 821 trap[™] Micro Spin Columns (ProtiFi) according to the manufacturer's instructions, where 822 samples were reduced with 40 mM 2-chloroacetamide (CAA, Sigma) and alkylated with 823 10 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; BondBreaker, Thermo 824 Fischer Scientific). Isolated proteins were digested at 1:25 trypsin to protein ratio at 37°C 825 overnight and eluted peptides were dried down using a CentriVap Benchtop Vacuum 826 Concentrator (Labconco). Fibroblasts and PBMCs spectral libraries were generating from 827 whole cell samples of either five healthy fibroblast controls or PBMC pellets isolated from 828 39 healthy individuals ranging from 0-17 years old. Fibroblast or PBMC pellets were 829 solubilized 5% SDS and 50 mM TEAB pH 8.5, and total protein determined by Pierce 830 bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher Scientific). A total of 25 µg for each control was processed using the S-Trap[™] Micro Spin Columns (ProtiFi), as 831 832 described above.

- 833 Peptides from HEK293T, fibroblast and PBMC samples were reconstituted in 0.5% formic 834 acid (FA) for fractionation. Fibroblast and PBMC control samples were pooled upon 835 reconstitution to create a single fibroblast, HEK293T and PBMC peptide mixture and 836 loaded onto a strong cation exchange (Empore Cation Exchange-SR, Supelco Analytical) 837 stage-tips made as described⁷⁸. Stage tips were washed with 20% acetonitrile (ACN) and 838 0.5% FA and eluted over seven fractions of increasing concentrations of ammonium 839 acetate (45-300 mM), 20% ACN and 0.5% FA for whole cell fibroblasts, PBMC and 840 HEK293T samples. HEK293T mitochondrial and supernatant samples, were collected 841 over five fractions. All samples underwent a final elution with 5% ammonium hydroxide 842 and 80% ACN, followed by concentration using a CentriVap Benchtop Vacuum 843 Concentrator (Labconoco). Fractions were desalted on SDB-XC (poly(styrene-divinyl-844 benzene): Supelco Analytical) stage tips made in-house as previously described⁷⁸.
- 845

846 Spectral Library Mass Spectrometry Data Dependent Acquisition

Fractions were reconstituted in 0.1% trifluoracetic acid (TFA) and 2% ACN and each library was analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) on an Orbitrap Eclipse Mass Spectrometer (Thermo Fischer Scientific) operating on DDA mode over a 125-minute gradient. Tryptic peptides were loaded onto an Acclaim Pepmap nano-trap column (Dinoex-C18, 100 Å, 75 μ m × 2 cm) at an isocratic flow of 5 μ l/min of 2% ACN and 0.1% FA for six minutes before switching with an Acclaim Pepmap RSLC analytical column (Dinoex-C18, 100 Å, 75 μ m × 50 cm). The separation of peptides was

854 performing using a nonlinear 125-minute gradient of solvent A (5% dimethyl sulphoxide 855 (DMSO), 0.1% FA) and solvent B (5% DMSO, 100% ACN, 0.1% FA). The flow gradient was (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-856 857 40% solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent 858 B, (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes 859 before the next injection. Briefly, the data was collected using positive polarity with a MS1 860 scan range of 375-1500 m/z and resolution set to 120,000. Other MS1 instrument 861 parameters include: ACG target of 4e5, maximum injection time of 50 ms and Isolation 862 window of 1.6. MS2 instrument parameters include: scan range of 150-2000 m/z, 863 resolution of 15,000, HCD collision energy of 30%, ACG target of 5e3, maximum injection 864 time of 22 ns and dynamic exclusion of 30 s. Raw files were imported into Spectronaut®79 865 (v.15.2.210819.50606 for HEK293T library, v.14.8.201029.4778 for fibroblasts library, v. 16.0.220606.53000 for PBMCs library) and the three libraries were generated using the 866 867 'Pulsar' option with default BGS Factory settings, searching against Uniprot human 868 database containing reviewed canonical and isoforms sequences (42,386 entries). The 869 resulting HEK293T library contained 194.270 precursors, the fibroblast library contained 870 131,627 precursors, and the PBMC library contained 148,522 precursors.

871

872 Sample Preparation of HEK293T, PBMC and Fibroblast Cell Lines

873 Whole cell pellets of HEK293T cells, PBMCs and fibroblasts were collected and washed 874 twice with PBS before resuspension in 5% SDS, 50 mM tetraethylammonium bromide (TEAB) pH 8.5 buffer and 125 U of benzonase per ml (Sigma-Aldrich). Skeletal muscle 875 876 samples were solubilized with a probe sonicator with 30% amplitude in 5% SDS, 50 mM 877 TEAB pH 8.5 buffer on ice with a cycle of 10 seconds on 10 seconds off for 1 minute and clarified at 16,000 x g for 5 minutes. Protein concentration was performed with Pierce 878 879 BCA Protein Assay Kit (Thermo Fisher Scientific) and 25 µg of each sample was aliquoted 880 in triplicates for patients and singlicate for individual controls (N=3-5). Samples were processed using S-trap[™] micro spin columns (ProtiFi) according to the manufacturer's 881 instructions. Proteins were digested with trypsin (Thermo Fisher Scientific) at 1:10 trypsin 882 883 to protein ratio. Peptides were dried down using a CentriVap Benchtop Vacuum 884 Concentrator (Labconco) and reconstituted in 45 µL 2% ACN. 0.1% trifluoroacetic acid 885 (TFA) and 2 µL injected for liquid chromatography tandem mass spectrometry (LC-MS/MS). Samples were analyzed for 125 minutes (HEK293T) or 95 minutes (Fibroblasts, 886 887 skeletal muscle, PBMCs) on an Orbitrap Eclipse mass spectrometer (Thermo Fisher 888 Scientific) operating in DIA mode.

889

890 Mass Spectrometry Data Independent Acquisition

891 Peptides were reconstituted in 45 µL of 2% ACN and 0.1% TFA and 2 µl was injected into 892 an Orbitrap Eclipse mass spectrometer (Thermo Fischer Scientific) for LC-MS/MS 893 analysis equipped with trap and analytical columns described above. All samples were 894 analysed with the mass spectrometer operating in DIA mode. The separation of peptides 895 was performed using a nonlinear gradient of solvent A and solvent B across 125-minutes for HEK293T knockout cell lines, and 95-minutes for all other sample types (fibroblasts, 896 897 PBMCs and skeletal muscle). Briefly, for the 125-minute method, the flow gradient was 898 (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-40% 899 solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent B, 900 (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes 901 before the next injection. The data was collected using positive polarity with a MS1 scan range of 350-1200 m/z at a resolution of 120,000. Other MS1 instrument parameters 902 include: ACG target of 1e6, maximum injection time of 50 ms, Isolation window of 24 with 903 904 1 m/z overlap. For MS2 parameters, the scan range was 200-2000 m/z at 15,000 905 resolution, HCD collision energy of 30%, AGC target of 1e6 and maximum injection time 906 of 22 ms. For the 95-minute method, the flow gradient was (i) 0-6 min at 3% solvent B, 907 (ii) 6-7 min at 3-4% solvent B, (iii) 7-82 min at 4-25% solvent B, (iv) 82-86 min at 25-40% 908 solvent B, (v) 86-87 min at 40-80% solvent B, (vi) 87-90 min at 80-80% solvent B, (vii) 90-909 91 min at 80-3% solvent B and equilibrated at 3% solvent B for 5 minutes before the next 910 injection. Instrument parameters were consistent with those used in the 125-minute 911 method described above, with changes made to the following parameters: MS1 scan 912 range of 350-1400 m/z, MS1 maximum injection time of 45 ms, Isolation window of 13.7 913 and MS2 ACG target of 5e5.

914

915 Proteomic data search

Raw data analysis was conducted with Spectronaut®79 (v.15.2.210819.50606) against the 916 917 spectral libraries generated above. Default BGS Factory search parameters were used 918 with changes made to exclude single hit proteins, no selection of 'Major Group Top N' 919 and 'Minor Group Top N' and data filtering setting set to 'Q-value' or 'Q-value sparse' with 920 'run-wise imputation' as an imputing strategy. 'Q-value' datasets (unimputed) were used 921 for generation of RCA values while 'Q-value sparse' with 'run-wise imputation' datasets 922 were used to generate volcano plots, heatmaps and correlation plots to reduce missing 923 values for visualization.

924

925 Protein filtering and clean up

926 Proteins were filtered in each cohort to ensure that the data was of high quality and with 927 a minimal amount of missing data for analysis. Proteins within the validation cohort (VC) 928 were filtered out if identified by a single peptide in all controls or proband samples. 929 maintaining proteins that were identified by >2 peptides in both groups. Proteins were 930 then filtered to least three or more valid values for the controls and at least two or more 931 valid values for the proband samples. For the knockout cohort (KC), proteins were filtered 932 out if identified by a single peptide in all controls and proband samples. Proteins were 933 then filtered to at least two valid values for the controls and at least two valid values for 934 the knockout sample. For the undiagnosed proband cohort (UDP), proteins were filtered 935 out if identified by a single peptide in all controls or proband samples. Proteins were then 936 filtered for 70% valid values for the controls due to the different number of controls per 937 batch and 70% valid values for the proband samples. For the supporting cohort (SC), 938 samples SC1, SC2, SC3 and SC5 proteins were filtered out if identified by a single peptide 939 in all controls or proband samples. Proteins were then filtered for 70% valid values for the 940 controls and 70% valid values for the proband samples. Sample SC4 had no filtering completed as this was a previously published dataset²¹ and the data was unlogged and 941 942 complex subunit gene names manually updated to match the current MitoCarta3.0 943 naming convention for Complex V subunits. For the 36 PBMC control samples (SC6-41), 944 proteins were filtered out if they were identified by a single peptide across all 36 samples 945 and further filtered for at least 70% valid values.

946

947 Relative Complex Abundance Plots.

948 Relative complex abundance (RCA) plots were generated for all VC, KC, SC and UDP 949 cohorts and plots can be viewed within the RDMS Explorer platform. All samples 950 underwent mitochondrial normalization where the mean of the mitochondrial proteins for 951 each specific sample was determined using the average of all control mitochondrial 952 proteins or proband mitochondrial proteins and then used as a normalization factor for 953 each group and applied to each sample. To develop the RCA plots, the average of the 954 proband and controls was determined and then transformed to log10. The difference 955 between the log10 of the proband and controls was determined and then unlogged. 956 Statistical difference between the control and proband complex subunits was determined 957 using a paired t-test and summary statistics including mean and the error bars indicating 958 standard deviation were determined for each complex and the graph plotted within R 959 (v.4.3.2). Complex subunits were determined using curated annotations from 960 MitoCarta3.0²⁸. Mitochondrial abundance plots were generated using log2 abundances 961 of MitoCarta '+' entries for each batch and significance performed with an ANOVA test.

962

963 Protein range graphs

Protein range graphs were developed using an in-house R script. The median of the 964 965 protein of interest in control samples is calculated as well as the median of the proband 966 replicates. The log2 fold-change is calculated between the proband and control and 967 converted to percentage for the proband as the abundance relative to the control median 968 for plotting. The range of the controls is also displayed as the abundance relative to the 969 control median. The log2 abundance per standard deviation (SD) is rounded to one 970 decimal place with the top axis SD present to determine how many standard deviations 971 the protein is from the control median.

972

973 Volcano and Correlation plots

974 The peptide and valid value cleaned matrices for all samples were annotated with MitoCarta3.0²⁸ entries in Perseus⁸⁰. All analyses were performed in Perseus v 1.6.14.0. 975 Volcano plots were visualized using scatter plot function from a two-sample t-test using 976 977 p-value threshold of 0.05 in Perseus. For the correlation plots (Fig 3B, Supplementary 978 Fig.2B), proteomic data searched with q-value sparse with run-wise imputation settings 979 were correlated via gene name using gene name entries and the logFCs in R and plotted 980 using scatter plot function in Perseus. For Fig. 4C, previously published data from 981 MRPL50 Fibroblasts²¹ were correlated with MRPL50 PBMCs using gene name entries 982 and the logFCs in R and plotted using scatter plot function in Perseus.

983

984 RDMS Explorer Website.

985 All the code used to develop the RDMS Explorer website 986 (<u>https://rdmassspec.shinyapps.io/RDMSExplorer/</u>) and in-house analysis performed in R 987 can be found at DOI: 10.5281/zenodo.12883603.

988

989 Heatmaps, Venn diagrams and Donut plots

990 For heatmaps output matrices searched with q-value sparse run-wise imputation settings 991 Spectronaut runs were log₂ transformed and a two-sided t-test using p-value for 992 truncation was performed in Perseus for each cell line against their respective batch 993 controls. The Morpheus software was used for heatmap visualization (https://software.broadinstitute.org/morpheus). For Supplementary Fig. 1A, proteins were 994 995 manually annotated based on MitoCarta3.0 as 'assembly factor' or 'complex I-V' and 996 subset for visualization in Morpheus using the following parameters metric 'one minus 997 Pearson correlation', linkage method 'average', cluster 'rows' and group columns by

998 'complex/assembly factor'. P-value results from t-test statistical analysis were used to visualize the significance of each data point by overlaying the p-value matrix onto the t-999 1000 test matrix in Morpheus and using the option size by 'p-value matrix' size minimum '0' 1001 and maximum '1.301' (p-value<0.05). For the correlation heatmap plot (Supplementary 1002 Fig. 2A), hierarchical clustering was used with the following parameters in Morpheus: 1003 metric 'one minus Pearson correlation', linkage method 'average' and cluster 'columns'. 1004 Topographical heatmaps (Supplementary Fig. 1B) were generated from log₂-transformed 1005 fold-change from t-test in Pymol using the PDB structures (CI: 5LDW, CII: 1ZOY, CIII: 1BGY, CIV: 5Z62, CV: 7AJD) as previously described²⁶. Venn diagrams were generated 1006 with DeepVenn⁸¹ using gene names. Green (diagnostic-grade) and amber (borderline 1007 1008 diagnostic-grade) lists for mitochondrial disease (v.0.787) and Mendeliome gene lists (v.0.12869) were retrieved from PanelApp Australia²⁷. Donut plots were generated in 1009 GraphPad Prism (v.10.2.0). 1010

1011

1012 RNA sequencing and transcriptomic analysis

RNA sequencing and analysis was performed as described²⁰. In brief, RNA was extracted 1013 from muscle using miRNeasy Mini Kit (Qiagen) and treated with RNase-Free DNase 1014 1015 (Qiagen) and RNA quality and quantity measured using TapeStation RNA ScreenTape analysis (Agilent) and Qubit RNA HS (Thermo Fisher Scientific). UDP4 underwent 1016 1017 RNAseg within a group of 10 undiagnosed patients with available muscle samples, all 1018 with a RNA integrity number of 7.2 - 8.9. The Kapa Biosystems mRNA Hyper Prep Kit 1019 was used to generate sequencing libraries from 500ng RNA, and paired-end sequencing 1020 on an Illumina instrument was performed at the Yale Center of Genome Analysis to achieve 50-100 million read coverage. 1021

1022

1023 For outlier detection, 100 control muscle samples were retrieved from GTEx using the 1024 Sequence Read Archive (SRA) toolkit and converted into FASTQ using Fastq-dump. Patient and control FASTQ files were aligned to hg38 human reference genome with 1025 1026 GENCODE v26 annotations using STAR (v2.5.3a), with twopassMode = 'Basic' to enable detection of novel splice junctions, and duplicates marked using Picard (v2.9). RNA-1027 1028 SeQC (v2.3.4) was used to generate quality metrics from STAR-aligned bam files. 1029 Outliers were removed per the following criteria: (a) <45 million QC-passed reads, (b) 1030 <18,000 genes detected and (c) manual identification via Principal Component Analysis. 1031 This resulted in the removal of 11 samples, leaving 89 control samples from muscle. Outlier expression was assessed using the DROP (Detection of RNA Outliers Pipeline) 1032 1033 pipeline v0.9.0 (https://github.com/gagneurlab/drop), with default settings⁸². Analysis was

1034 restricted to 6106 genes, which included Mendeliome and 'MitoExome' genes, as 1035 described previously²⁰.

1036

1037 *cDNA studies*

1038 The total RNA extracted from skeletal muscle for RNA sequencing was also synthesized 1039 into cDNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific) as per both manufacturer's protocols and as described previously⁸³. To 1040 1041 examine mRNA splicing in CCDC47, PCR primers (5' GCGTGACTGAGCTACGGTT 3'; 5' CTCTGGGATGGCTTTACATGG 3') were designed to amplify the entire ORF from 1042 cDNA. PCR products were analyzed on 1% agarose (Bioline) gels using a 1-kb Plus DNA 1043 1044 Ladder (Thermo Fisher Scientific) prior to cloning into a pCR2.1-TOPO vector using the 1045 TOPO TA cloning kit (Thermo Fisher Scientific) and transformation into TOP10 competent cells (Thermo Fisher Scientific). Individual colonies were examined and then underwent 1046

- 1047 sanger sequencing.
- 1048

1049 Conflict of Interest

- 1050 The authors declare that the research was conducted in the absence of any commercial
- 1051 or financial relationships that could be construed as a potential conflict of interest.
- 1052

1053 MitoMDT Diagnostic Network for Genomics and Omics

David R Thorburn, Carolyn M Sue, Aleksandra Filipovska, Michael T Ryan, David A
Stroud, Diana Stojanovski, David Coman, Sean Murray, Ryan L Davis, John
Christodoulou, Phillipa J Lamont, Suzanne CEH Sallevelt, Roula Ghaoui, Cas Simons,
Stefan J Siira, Shanti Balasubramaniam, Alison G Compton, Daniel G MacArthur, Nicole
J Lake, Amanda Samarasinghe, Yoni Elbaum, Catherine Atthow, Pauline McGrath,
Ellenore M Martin, Madeleine Harris, Tegan Stait, Leah E Frajman, Simone Tregoning

1060

1061 Author contribution

- 1062 Conceptualization: DHH, DRT, DAS
- 1063 Methodology: DHH, NJC, LNS, NJL, LuEF, SSCA, TS, ST, LeEF, DRLR, MB, BoR, AGC,
- 1064 VK, CA
- 1065 Investigation: DHH, MB, BrR, MJW, AV, CB, HP, JL, ZS, RM, RWT, AGC, WB
- 1066 Visualization: DHH, NJC, LNS, NJL, SSCA
- 1067 Website design and coding: NJC
- 1068 Funding acquisition: DHH, JC, AGC, DRT, DAS
- 1069 Project administration: AS, RB, DRT, DAS

- 1070 Supervision: PM, ML, RM, RWT, MTR, ZS, JC, AGC, DRT, DAS
- 1071 Writing original draft: DHH, DRT, DAS
- 1072 Writing review & editing: all authors reviewed and edited the manuscript
- 1073

1074 Funding

This research was supported by Australian National Health and Medical Research 1075 Council (NHMRC) Project and Ideas grants (1140906 to DAS; 1164479 to DRT; 2010939 1076 to MTR), Investigator Fellowships (2009732 to DAS, 2010149 to LuEF and 1155244 to 1077 DRT) and a Principal Research Fellowship (1155244 to DRT) along with funding by 1078 1079 Australian Genomics Health Alliance (Australian Genomics) NHMRC Targeted Call for Research grant GNT1113531. Additional support came from the Australian Medical 1080 Research Future Fund Genomics Health Futures Mission (2007959 to DRT) and Acute 1081 Care Genomics (GHFM76747). The US Department of Defense Congressionally Directed 1082 1083 Medical Research Programs (PR170396 to DRT). We thank the Mito Foundation for the 1084 provision of instrumentation through research equipment grants to DAS and DHH. Additionally, LuEF acknowledges support from the Mito Foundation. This work was also 1085 1086 supported by grants from Royal Children's Hospital Foundation [2021-1377]. Work at the MCRI is supported through the Victorian Government's Operational Infrastructure 1087 1088 Support Program. RWT is funded by the Wellcome Centre for Mitochondrial Research 1089 (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Medical 1090 Research Council (MR/W019027/1), the Lily Foundation, Mito Foundation, the Pathological Society, the UK NIHR Biomedical Research Centre for Ageing and Age-1091 1092 related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust, 1093 LifeArc and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of 1094 Adults and Children.

1095

1096 Acknowledgments

1097 We acknowledge and thank all the families who contributed to this study. We thank all 1098 members of the Stroud and Stojanovski lab for input into experimental design and interpretation of data. We thank the Bio21 Mass Spectrometry and Proteomics Facility 1099 (MMSPF) for the provision of instrumentation, training, and technical support. The Chair 1100 in Genomic Medicine awarded to JC is generously supported by The Royal Children's 1101 Hospital Foundation. The authors thank staff of the Pathology Collection Department at 1102 The Royal Children's Hospital for obtaining the consent of participants and the collection 1103 1104 of samples. The authors thank staff of the Anaesthetic and Surgical Departments at the 1105 Royal Children's Hospital.

1106

1107 Data Availability Statement

1108 The mass spectrometry proteomic data will be deposited to the ProteomeXchange 1109 Consortium via the PRIDE partner repository upon publication. De-identified genomic

- 1110 data from this study are available for ethically approved research. For queries about the
- 1111 genomic data sets please contact: david.thorburn@mcri.edu.au.
- 1112

1113 References

- 11141.Haack, T.B. et al. Molecular diagnosis in mitochondrial complex I deficiency using1115exome sequencing. J Med Genet 49, 277-283 (2012).
- 1116 2. Taylor, R.W. *et al.* Use of whole-exome sequencing to determine the genetic basis of
 1117 multiple mitochondrial respiratory chain complex deficiencies. *JAMA* **312**, 68-77
 1118 (2014).
- 1119 3. Ohtake, A. *et al.* Diagnosis and molecular basis of mitochondrial respiratory chain
 1120 disorders: exome sequencing for disease gene identification. *Biochim Biophys Acta*1121 **1840**, 1355-1359 (2014).
- Wortmann, S.B., Koolen, D.A., Smeitink, J.A., van den Heuvel, L. & Rodenburg, R.J.
 Whole exome sequencing of suspected mitochondrial patients in clinical practice. *J Inherit Metab Dis* 38, 437-443 (2015).
- 11255.Davis, R.L. et al. Use of Whole-Genome Sequencing for Mitochondrial Disease1126Diagnosis. Neurology 99, e730-e742 (2022).
- Frazier, A.E., Thorburn, D.R. & Compton, A.G. Mitochondrial energy generation
 disorders: genes, mechanisms, and clues to pathology. *J Biol Chem* 294, 5386-5395
 (2019).
- 1130 7. Gorman, G.S. *et al.* Mitochondrial diseases. *Nat Rev Dis Primers* **2**, 16080 (2016).
- 11318.Skladal, D., Halliday, J. & Thorburn, D.R. Minimum birth prevalence of mitochondrial1132respiratory chain disorders in children. Brain 126, 1905-1912 (2003).
- 11339.Smeets, H.J.M., Sallevelt, S. & Herbert, M. Reproductive options in mitochondrial1134disease. Handb Clin Neurol 194, 207-228 (2023).
- Frazier, A.E., Vincent, A.E., Turnbull, D.M., Thorburn, D.R. & Taylor, R.W.
 Assessment of mitochondrial respiratory chain enzymes in cells and tissues.
 Methods Cell Biol 155, 121-156 (2020).
- 1138 11. Kremer, L.S. *et al.* Genetic diagnosis of Mendelian disorders via RNA sequencing.
 1139 Nat Commun **8**, 15824 (2017).
- 114012.Yepez, V.A. et al. Clinical implementation of RNA sequencing for Mendelian disease1141diagnostics. Genome Med 14, 38 (2022).
- 114213.Fresard, L. *et al.* Identification of rare-disease genes using blood transcriptome1143sequencing and large control cohorts. Nat Med 25, 911-919 (2019).
- 1144 14. Murdock, D.R. *et al.* Transcriptome-directed analysis for Mendelian disease
 1145 diagnosis overcomes limitations of conventional genomic testing. *J Clin Invest* 131
 1146 (2021).
- 114715.Chen, E. et al. Rates and Classification of Variants of Uncertain Significance in1148Hereditary Disease Genetic Testing. JAMA Netw Open 6, e2339571 (2023).
- 114916.Alston, C.L., Stenton, S.L., Hudson, G., Prokisch, H. & Taylor, R.W. The genetics of1150mitochondrial disease: dissecting mitochondrial pathology using multi-omic1151pipelines. J Pathol 254, 430-442 (2021).

1152 1153 1154	17.	Kopajtich, R. <i>et al.</i> Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders. <i>medRxiv</i> , 2021, 2003, 2009, 21253187 (2021).
1155	18	Xiao $O \&$ Lauschke V M The prevalence genetic complexity and population-
1156	10.	specific founder effects of human autosomal recessive disorders NPI Genom Med
1150		
1152	10	Sabri N et al Widespread macromolecular interaction perturbations in human
1150	15.	denotic disorders. Coll 161 , 647, 660 (2015)
1160	20	America al S. C. et al. Multi-omies identifies large miterihosemal subunit
1161	20.	instability sourced by notheganic MPDI 20 verients as a source of pediatric apost
1162		mitochondrial discasso. Hum Mol Conot 22 , 2441, 2454 (2022)
1162	21	Rekeshalizadah S. at al. Deficiency of the mitochondrial ribosomal subunit
1164	21.	MRDL 50, aquiana autonomal ropposivo avadromio promoturo avarion inpufficionev
1165		Hum Const 142 , 870, 007 (2022)
1165	22	Holmon, C. at al. Multionia analysis alusidates Complex I defisioney acused by a
1167	22.	doon intronio variant in NDUEP10. Hum Mutat 42 , 10, 24 (2021)
1160	^ 2	Herveth P. et al. Childhood ansat mitochondrial myonethy and lactic acidesis
1160	23.	norvatil, R. et al. Cilitation of Set mitochondrial myopathy and factic actuosis
1170		Mod Const 20 , 912, 916 (2002)
1170	24	Van Hauta I. at al. TEEM varianta impair mitachandrial transprintion equaing
1170	24.	vali Haute, L. et al. TEFM valiants impair initiochonunat transcription causing
1172	25	Lake N L et al. Piellelie Mutations in MPDS24 Load to Instability of the Small
1173	25.	Lake, N.J. et al. Dialletic mutations in MRF334 Lead to instability of the Small
1175	26	Stroud D A at al Accessory subunits are integral for accembly and function of
1175	20.	Stroud, D.A. et al. Accessory suburits are integration assembly and function of
1170	27	Martin A.B. et al. DanalAnn aroudaeuraea evnert knowledge to establish
1170	27.	Martin, A.R. et al. PanetApp crowdsources expert knowledge to establish
1170	20	Consensus diagnostic gene panets. <i>Nat Genet</i> 51 , 1560-1565 (2019).
11/9	28.	Rain, S. et al. MiloCarta3.0: an updated milochondrial proteome now with sub-
1100		DIGATELLE LOCALIZATION AND PATHWAY ANNOLATIONS. NUCLEIC ACIUS RES 49, D1541-
1101	20	DI547 (2021). Cronata C at al High intensity training induces non-staichismatric changes in the
1102	29.	Granata, C. et al. Figh-intensity training induces non-stolchometric changes in the
1103		recentration chain content. Net Commun 19 , 7056 (2021)
1104	20	The mass of the strend DA. The shurp D. D. Stever, D. M. Investigation of evidentive
1100	30.	mompson, K., Stroud, D.A., morburn, D.R. & raytor, R.W. investigation of oxidative
		Clin Neurol 104 , 107, 120 (2022)
110/	21	Cull Neuloi 194, 127-139 (2023).
1100	31.	bermer, F.P. et al. Diagnostic chiena for respiratory chain disorders in adults and
1189	22	Children. Neurology 59 , 1406-1411 (2002).
1190	32.	Acin-Perez, R. et al. Respiratory complex in is required to maintain complex in manual complex in manual complex in the second s
1191	00	mammalian mitochondria. <i>Mol Cell</i> 13 , 805-815 (2004).
1192	చ చ.	Kanman, S. et al. Leign syndrome: cunical features and biochemical and DNA
1193	0.4	apnormauties. Ann Neurol 39 , 343-351 (1996).
1194	34.	IUCKER, E.J. et al. MUTATIONS IN MITEMI UNDERLIE A NUMAN disorder of formylation
1195		causing impaired mitochondrial translation. Cell Metab 14 , 428-434 (2011).

1196 1197	35.	Massa, V. <i>et al</i> . Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. <i>Am J Hum Genet</i> 82 , 1281, 1280 (2008)
1198 1199 1200	36.	Hock, D.H., Robinson, D.R.L. & Stroud, D.A. Blackout in the powerhouse: clinical phenotypes associated with defects in the assembly of OXPHOS complexes and
1201 1202 1203	37.	Zong, S. <i>et al.</i> Structure of the intact 14-subunit human cytochrome c oxidase. <i>Cell Res</i> (2018).
1204 1205	38.	Signes, A. & Fernandez-Vizarra, E. Assembly of mammalian oxidative phosphorylation complexes I-V and supercomplexes. <i>Essays Biochem</i> 62 , 255-270
1208 1207 1208 1209	39.	Cizkova, A. <i>et al.</i> TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy. <i>Nat Genet</i> 40 , 1288-1290 (2008).
1210 1211 1212	40.	Catteruccia, M. <i>et al.</i> Persistent pulmonary arterial hypertension in the newborn (PPHN): a frequent manifestation of TMEM70 defective patients. <i>Mol Genet Metab</i> 111 , 353-359 (2014).
1213 1214	41.	Torraco, A. <i>et al.</i> TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex V biogenesis. <i>Neurogenetics</i> 13 , 375-386 (2012).
1215 1216 1217	42.	Braczynski, A.K. <i>et al</i> . ATP synthase deficiency due to TMEM70 mutation leads to ultrastructural mitochondrial degeneration and is amenable to treatment. <i>Biomed Res Int</i> 2015 , 462592 (2015).
1218 1219	43.	Magner, M. <i>et al.</i> TMEM70 deficiency: long-term outcome of 48 patients. <i>J Inherit</i> <i>Metab Dis</i> 38 , 417-426 (2015).
1220 1221	44.	Sanchez-Caballero, L. <i>et al.</i> TMEM70 functions in the assembly of complexes I and V. <i>Biochim Biophys Acta Bioenerg</i> 1861 , 148202 (2020).
1222 1223	45.	Guerrero-Castillo, S. <i>et al</i> . The Assembly Pathway of Mitochondrial Respiratory Chain Complex I. <i>Cell Metab</i> 25 , 128-139 (2017).
1224 1225 1226	46.	Mowat, D. <i>et al.</i> Respiratory chain complex III [correction of complex] in deficiency with pruritus: a novel vitamin responsive clinical feature. <i>J Pediatr</i> 134 , 352-354 (1999).
1227 1228 1229	47.	Morimoto, M. <i>et al.</i> Bi-allelic CCDC47 Variants Cause a Disorder Characterized by Woolly Hair, Liver Dysfunction, Dysmorphic Features, and Global Developmental Delay. <i>Am J Hum Genet</i> 103 , 794-807 (2018).
1230 1231	48.	Yang, Q. <i>et al</i> . Clinical and genetic analysis of trichohepatoneurodevelopmental syndrome caused by a CCDC47 variant. <i>Heliyon</i> 10 , e27955 (2024).
1232 1233	49.	Iannello, G. <i>et al</i> . Simple, Fast, and Efficient Method for Derivation of Dermal Fibroblasts From Skin Biopsies. <i>Curr Protoc</i> 3 , e714 (2023).
1234 1235	50.	Amunts, A., Brown, A., Toots, J., Scheres, S.H.W. & Ramakrishnan, V. Ribosome. The structure of the human mitochondrial ribosome. <i>Science</i> 348 , 95-98 (2015).
1236 1237 1238	51.	Bakker, H.D. <i>et al</i> . Human alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency: no association with neuroaxonal dystrophy? <i>Eur J Hum Genet</i> 9 , 91-96 (2001).

1239 1240	52.	Sung, A.Y. <i>et al.</i> Systematic analysis of NDUFAF6 in complex I assembly and mitochondrial disease. <i>Nat Metab</i> 6 , 1128-1142 (2024).
1241	53.	Pagliarini, D.J. et al. A mitochondrial protein compendium elucidates complex I
1242		disease biology. <i>Cell</i> 134 , 112-123 (2008).
1243	54.	McKenzie, M. <i>et al.</i> Mutations in the gene encoding C8orf38 block complex I
1244		assembly by inhibiting production of the mitochondria-encoded subunit ND1. J Mol
1245		<i>Biol</i> 414 . 413-426 (2011).
1246	55.	Baide-Mairena, H. et al. Mutations in the mitochondrial complex I assembly factor
1247		NDUFAF6 cause isolated bilateral striatal necrosis and progressive dystonia in
1248		childhood. Mol Genet Metab 126 , 250-258 (2019).
1249	56.	Hartmannova, H. et al. Acadian variant of Fanconi syndrome is caused by
1250		mitochondrial respiratory chain complex I deficiency due to a non-coding mutation
1251		in complex I assembly factor NDUFAF6. <i>Hum Mol Genet</i> 25 , 4062-4079 (2016).
1252	57.	Kim, J., Lee, J. & Jang, D.H. NDUFAF6-Related Leigh Syndrome Caused by Rare
1253		Pathogenic Variants: A Case Report and the Focused Review of Literature. <i>Front</i>
1254		Pediatr 10 , 812408 (2022).
1255	58.	Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare
1256		diseases: analysis of the Orphanet database. <i>Eur J Hum Genet</i> 28 , 165-173 (2020).
1257	59.	Van Bergen, N.J. et al. Severe NAD(P)HX Dehydratase (NAXD) Neurometabolic
1258		Syndrome May Present in Adulthood after Mild Head Trauma. Int J Mol Sci 24 (2023).
1259	60.	Tucker, E.J. et al. Premature Ovarian Insufficiency in CLPB Deficiency:
1260		Transcriptomic, Proteomic and Phenotypic Insights. J Clin Endocrinol Metab 107 ,
1261		3328-3340 (2022).
1262	61.	Van Bergen, N.J. <i>et al.</i> Biallelic Variants in PYROXD2 Cause a Severe Infantile
1263		Metabolic Disorder Affecting Mitochondrial Function. Int J Mol Sci 23 (2022).
1264	62.	Frazier, A.E. et al. Fatal perinatal mitochondrial cardiac failure caused by recurrent
1265		de novo duplications in the ATAD3 locus. <i>Med (N Y)</i> 2 , 49-73 (2021).
1266	63.	Borna, N.N. et al. Mitochondrial ribosomal protein PTCD3 mutations cause
1267		oxidative phosphorylation defects with Leigh syndrome. <i>Neurogenetics</i> 20 , 9-25
1268		(2019).
1269	64.	Van Bergen, N.J. et al. Mutations in the exocyst component EXOC2 cause severe
1270		defects in human brain development. <i>J Exp Med</i> 217 (2020).
1271	65.	Lunke, S. et al. Integrated multi-omics for rapid rare disease diagnosis on a national
1272		scale. <i>Nat Med</i> 29 , 1681-1691 (2023).
1273	66.	Formosa, L.E., Dibley, M.G., Stroud, D.A. & Ryan, M.T. Building a complex complex:
1274		Assembly of mitochondrial respiratory chain complex I. Semin Cell Dev Biol 76,
1275		154-162 (2018).
1276	67.	Frederiksen, S.D. et al. Rare disorders have many faces: in silico characterization of
1277		rare disorder spectrum. Orphanet J Rare Dis 17 , 76 (2022).
1278	68.	Turner, T.N. et al. Proteins linked to autosomal dominant and autosomal recessive
1279		disorders harbor characteristic rare missense mutation distribution patterns. Hum
1280		Mol Genet 24 , 5995-6002 (2015).
1281	69.	Dofash, L.N. <i>et al</i> . Biallelic variants in HMGCS1 are a novel cause of
1282		rare rigid spine syndrome. <i>medRxiv</i> , 2023.2010.2025.23297129 (2023).

1283	70.	Gorzynski, J.E. et al. Ultrarapid Nanopore Genome Sequencing in a Critical Care
1284		Setting. <i>N Engl J Med</i> 386 , 700-702 (2022).
1285	71.	Australian Genomics Health Alliance Acute Care, F. et al. Feasibility of Ultra-Rapid
1286		Exome Sequencing in Critically III Infants and Children With Suspected Monogenic
1287		Conditions in the Australian Public Health Care System. JAMA 323, 2503-2511
1288		(2020).
1289	72.	Dimmock, D. et al. Project Baby Bear: Rapid precision care incorporating rWGS in 5
1290		California children's hospitals demonstrates improved clinical outcomes and
1291		reduced costs of care. <i>Am J Hum Genet</i> 108 , 1231-1238 (2021).
1292	73.	Guzman, U.H. et al. Ultra-fast label-free quantification and comprehensive
1293		proteome coverage with narrow-window data-independent acquisition. Nat
1294		Biotechnol (2024).
1295	74.	Yang, Y. et al. Clinical whole-exome sequencing for the diagnosis of mendelian
1296		disorders. <i>N Engl J Med</i> 369 , 1502-1511 (2013).
1297	75.	Akesson, L.S. et al. Early diagnosis of Pearson syndrome in neonatal intensive care
1298		following rapid mitochondrial genome sequencing in tandem with exome
1299		sequencing. <i>Eur J Hum Genet</i> 27 , 1821-1826 (2019).
1300	76.	Hoq, M. et al. A prospective, cross-sectional study to establish age-specific
1301		reference intervals for neonates and children in the setting of clinical biochemistry,
1302		immunology and haematology: the HAPPI Kids study protocol. BMJ Open 9,
1303		e025897 (2019).
1304	77.	Robinson, D.R.L. et al. Applying Sodium Carbonate Extraction Mass Spectrometry
1305		to Investigate Defects in the Mitochondrial Respiratory Chain. Front Cell Dev Biol
1306		10 , 786268 (2022).
1307	78.	Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated
1308		proteomic-sample processing applied to copy-number estimation in eukaryotic
1309		cells. <i>Nat Methods</i> 11 , 319-324 (2014).
1310	79.	Bruderer, R. et al. Extending the limits of quantitative proteome profiling with data-
1311		independent acquisition and application to acetaminophen-treated three-
1312		dimensional liver microtissues. <i>Mol Cell Proteomics</i> 14 , 1400-1410 (2015).
1313	80.	Tyanova, S. & Cox, J. Perseus: A Bioinformatics Platform for Integrative Analysis of
1314		Proteomics Data in Cancer Research. Methods Mol Biol 1711 , 133-148 (2018).
1315	81.	Hulsen, T. arXiv:2210.04597 (2022).
1316	82.	Yepez, V.A. et al. Detection of aberrant gene expression events in RNA sequencing
1317		data. <i>Nat Protoc</i> 16 , 1276-1296 (2021).
1318	83.	Calvo, S.E. et al. Molecular diagnosis of infantile mitochondrial disease with
1319		targeted next-generation sequencing. Sci Transl Med 4 , 118ra110 (2012).
1320		